This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
older adults | 786 |
risk factors | 394 |
immune system | 316 |
health care | 309 |
mean age | 307 |
older people | 298 |
age groups | 295 |
age group | 274 |
renal failure | 256 |
blood pressure | 246 |
immune response | 241 |
physical activity | 226 |
public health | 222 |
mg kg | 220 |
years old | 205 |
abstract background | 184 |
muscle mass | 182 |
nephrotic syndrome | 179 |
renal function | 178 |
intensive care | 176 |
increased risk | 168 |
mg dl | 164 |
significantly higher | 164 |
risk factor | 156 |
logistic regression | 155 |
infectious diseases | 154 |
skeletal muscle | 150 |
mental health | 146 |
control group | 146 |
urinary tract | 144 |
bone marrow | 140 |
renal disease | 140 |
united states | 139 |
systematic review | 137 |
oxidative stress | 136 |
social distancing | 136 |
cardiovascular disease | 135 |
physical performance | 132 |
old age | 130 |
aged years | 129 |
cohort study | 128 |
ml min | 125 |
acute respiratory | 125 |
elderly patients | 124 |
older persons | 124 |
statistically significant | 123 |
hong kong | 117 |
heart failure | 114 |
related diseases | 113 |
elderly people | 112 |
long term | 111 |
breast cancer | 111 |
innate immune | 110 |
cognitive impairment | 109 |
mitochondrial function | 109 |
mitochondrial dysfunction | 108 |
one patient | 108 |
clinical trials | 108 |
side effects | 106 |
metabolic syndrome | 105 |
gene expression | 104 |
among older | 103 |
body mass | 101 |
two groups | 100 |
kidney disease | 99 |
renal biopsy | 99 |
high risk | 98 |
median age | 98 |
kg day | 98 |
peripheral blood | 97 |
muscle strength | 97 |
heart disease | 97 |
respiratory tract | 97 |
grip strength | 97 |
coronavirus disease | 96 |
significant differences | 96 |
macular degeneration | 96 |
mechanical ventilation | 94 |
bronze age | 94 |
significantly lower | 93 |
mass index | 93 |
immune responses | 93 |
ng ml | 91 |
one year | 91 |
related macular | 89 |
care unit | 88 |
immune cells | 87 |
stem cell | 86 |
present study | 86 |
doc id | 85 |
gait speed | 85 |
subjective age | 85 |
cord uid | 85 |
health services | 85 |
older patients | 84 |
birth weight | 84 |
chronic renal | 83 |
significant difference | 82 |
primary care | 82 |
physical function | 82 |
life expectancy | 81 |
family members | 81 |
new york | 80 |
tract infections | 79 |
cd cd | 79 |
results suggest | 79 |
two patients | 79 |
regression analysis | 79 |
renal transplantation | 78 |
respiratory syndrome | 78 |
year old | 78 |
serum creatinine | 77 |
higher risk | 77 |
older age | 76 |
elderly persons | 76 |
clinical features | 75 |
chronic inflammation | 75 |
body weight | 75 |
pediatric patients | 74 |
general population | 74 |
tract infection | 74 |
family history | 74 |
daily living | 74 |
significantly associated | 74 |
mortality rate | 74 |
stage renal | 74 |
elderly population | 73 |
respiratory failure | 73 |
severe acute | 72 |
mortality rates | 72 |
fatality rate | 72 |
sectional study | 71 |
patients aged | 71 |
important role | 70 |
least one | 70 |
protein intake | 70 |
chronic diseases | 70 |
educational attainment | 69 |
pg ml | 69 |
nk cells | 69 |
may also | 69 |
nitric oxide | 69 |
hematopoietic stem | 68 |
adverse events | 68 |
health status | 67 |
life satisfaction | 67 |
inflammatory response | 66 |
replacement therapy | 66 |
cancer risk | 66 |
cognitive function | 66 |
respiratory distress | 65 |
acute renal | 65 |
novel coronavirus | 65 |
adaptive immune | 64 |
may lead | 64 |
hiv aids | 64 |
age range | 63 |
old boy | 63 |
nervous system | 63 |
children aged | 63 |
infectious disease | 63 |
viral infections | 63 |
inflammatory cytokines | 63 |
young people | 63 |
body composition | 62 |
patients received | 62 |
dwelling older | 62 |
cytokine storm | 62 |
health outcomes | 61 |
term care | 61 |
chronological age | 61 |
clinical practice | 60 |
flow cytometry | 60 |
peritoneal dialysis | 60 |
two years | 59 |
nursing homes | 59 |
primary immunodeficiency | 59 |
cognitive decline | 59 |
asthmatic patients | 58 |
even though | 58 |
findings suggest | 58 |
weight loss | 58 |
first year | 57 |
functional decline | 57 |
clinical trial | 57 |
health promotion | 56 |
lung disease | 56 |
health problems | 56 |
old girl | 56 |
world health | 56 |
stem cells | 56 |
group i | 55 |
reported cases | 55 |
previous studies | 55 |
diabetes mellitus | 55 |
among patients | 55 |
glomerular filtration | 55 |
autosomal recessive | 54 |
care services | 54 |
lung cancer | 54 |
age years | 54 |
data collection | 54 |
immune function | 54 |
healthy children | 53 |
case report | 53 |
nutritional status | 53 |
working group | 53 |
high levels | 53 |
age distribution | 53 |
cardiovascular diseases | 53 |
myocardial infarction | 53 |
developing countries | 53 |
factors associated | 52 |
older women | 52 |
average age | 52 |
uric acid | 52 |
linear regression | 52 |
controlled trial | 52 |
confidence interval | 52 |
three patients | 51 |
end stage | 51 |
family care | 51 |
prospective study | 51 |
cellular senescence | 51 |
randomized controlled | 51 |
renal insufficiency | 51 |
healthy aging | 50 |
social support | 50 |
clinical course | 50 |
liver transplantation | 50 |
university hospital | 50 |
young adults | 50 |
epithelial cells | 49 |
type diabetes | 49 |
chronic kidney | 49 |
assessed using | 49 |
adipose tissue | 49 |
significantly increased | 49 |
filtration rate | 49 |
transplant recipients | 49 |
cardiovascular risk | 49 |
renal transplant | 49 |
growth factor | 49 |
type i | 49 |
significantly different | 49 |
care system | 48 |
patients without | 48 |
adverse effects | 48 |
kidney transplantation | 48 |
european countries | 48 |
one case | 48 |
previously reported | 47 |
health organization | 47 |
home care | 47 |
determine whether | 47 |
healthy controls | 47 |
prospective cohort | 47 |
converting enzyme | 47 |
year period | 46 |
influenza vaccination | 46 |
physical health | 46 |
socioeconomic status | 46 |
control study | 46 |
physical exercise | 46 |
exome sequencing | 46 |
case fatality | 46 |
drug use | 46 |
younger adults | 46 |
aging process | 46 |
blood samples | 46 |
pediatric nephrology | 46 |
age classes | 45 |
acute rejection | 45 |
cssa recipients | 45 |
per year | 45 |
neovascular age | 45 |
emergency department | 45 |
frail older | 45 |
dendritic cells | 44 |
proinflammatory cytokines | 44 |
generational differences | 44 |
later life | 44 |
clinical presentation | 44 |
people aged | 44 |
cardiac surgery | 44 |
cell function | 44 |
combined immunodeficiency | 44 |
cd cells | 43 |
age class | 43 |
nursing home | 43 |
respiratory infections | 43 |
group ii | 43 |
old male | 43 |
made available | 43 |
pulmonary disease | 43 |
physical frailty | 43 |
cell types | 42 |
total number | 42 |
international license | 42 |
white matter | 42 |
disease control | 42 |
lung function | 42 |
author funder | 42 |
stool samples | 42 |
genetic testing | 42 |
patients showed | 42 |
senescent cells | 42 |
standard deviation | 42 |
copyright holder | 42 |
social constructionist | 42 |
granted medrxiv | 42 |
physical examination | 41 |
different age | 41 |
healthy ageing | 41 |
normal range | 41 |
odds ratio | 41 |
frailty status | 41 |
retrospective study | 41 |
regression model | 41 |
zinc supplementation | 41 |
urinary protein | 41 |
gestational age | 41 |
endothelial cells | 40 |
may help | 40 |
health system | 40 |
complete remission | 40 |
central nervous | 40 |
fatality rates | 40 |
adult patients | 40 |
viral infection | 39 |
performed using | 39 |
data suggest | 39 |
pilot study | 39 |
syndrome coronavirus | 39 |
increasing age | 39 |
autosomal dominant | 39 |
recent years | 39 |
among women | 38 |
immune deficiency | 38 |
intervention group | 38 |
natural history | 38 |
also found | 38 |
much higher | 38 |
health insurance | 38 |
significant increase | 38 |
coronary heart | 38 |
recurrent infections | 38 |
social isolation | 38 |
low muscle | 38 |
cell death | 38 |
related changes | 38 |
nk cell | 38 |
distress syndrome | 38 |
depressive symptoms | 38 |
measured using | 37 |
biological aging | 37 |
results show | 37 |
high prevalence | 37 |
national health | 37 |
immune dysregulation | 37 |
frailty index | 37 |
renal tubular | 37 |
analysis showed | 37 |
clinical characteristics | 37 |
regression models | 37 |
lifespan perspective | 37 |
poster sessions | 37 |
cell transplantation | 37 |
critically ill | 37 |
advanced age | 37 |
controlled trials | 37 |
spinal cord | 37 |
bubonic plague | 37 |
compound heterozygous | 37 |
clinical data | 37 |
handgrip strength | 36 |
air pollution | 36 |
chain cleavage | 36 |
younger age | 36 |
study population | 36 |
older workers | 36 |
polymerase chain | 36 |
sample size | 36 |
constructionist perspective | 36 |
current study | 36 |
per day | 36 |
cohort effects | 36 |
functional capacity | 36 |
iga nephropathy | 36 |
older men | 36 |
machine learning | 36 |
animal models | 36 |
chain reaction | 36 |
statistical analysis | 35 |
several studies | 35 |
fatty acids | 35 |
significant correlation | 35 |
multivariate analysis | 35 |
may play | 35 |
mycophenolate mofetil | 35 |
walking speed | 35 |
magnetic resonance | 35 |
chronic obstructive | 35 |
early diagnosis | 35 |
may contribute | 35 |
york city | 35 |
blood flow | 35 |
demographic data | 35 |
hip fracture | 35 |
hiv infection | 35 |
urban areas | 35 |
cognitive frailty | 35 |
year follow | 35 |
low levels | 35 |
adults aged | 35 |
inclusion criteria | 35 |
united kingdom | 35 |
contact matrices | 35 |
obstructive pulmonary | 35 |
two weeks | 35 |
abdominal pain | 35 |
six months | 35 |
results indicate | 35 |
last decade | 34 |
developmental delay | 34 |
confidence intervals | 34 |
mean duration | 34 |
left ventricular | 34 |
environmental factors | 34 |
total population | 34 |
high level | 34 |
contact patterns | 34 |
women aged | 34 |
preliminary results | 34 |
diagnostic criteria | 34 |
segmental glomerulosclerosis | 34 |
patients admitted | 34 |
wide range | 34 |
lupus nephritis | 34 |
longitudinal study | 34 |
term follow | 34 |
protective effect | 34 |
biological age | 33 |
liver disease | 33 |
folic acid | 33 |
cervical cancer | 33 |
graft survival | 33 |
significant association | 33 |
two cases | 33 |
mri brain | 33 |
recent studies | 33 |
innate immunity | 33 |
palliative care | 33 |
near east | 33 |
clinical manifestations | 33 |
months later | 33 |
pulmonary hypertension | 33 |
muscle function | 33 |
predictive value | 33 |
severe covid | 33 |
community health | 33 |
first time | 33 |
smooth muscle | 33 |
creatinine clearance | 33 |
cytokine production | 33 |
muscle weakness | 33 |
social security | 32 |
graft function | 32 |
alcohol consumption | 32 |
chronic disease | 32 |
serum levels | 32 |
heart rate | 32 |
higher levels | 32 |
systemic inflammation | 32 |
health needs | 32 |
statistical significance | 32 |
associated genes | 32 |
contact matrix | 32 |
mononuclear cells | 32 |
dmsa scan | 32 |
old female | 32 |
three months | 32 |
cell responses | 32 |
within hours | 32 |
alport syndrome | 32 |
psychological distress | 32 |
version posted | 32 |
amino acids | 32 |
cell receptor | 32 |
life span | 32 |
four patients | 32 |
steroid therapy | 32 |
functional status | 32 |
class i | 31 |
may provide | 31 |
study design | 31 |
human lung | 31 |
lung transplantation | 31 |
early detection | 31 |
th percentile | 31 |
control groups | 31 |
nlrp inflammasome | 31 |
drug users | 31 |
multiple sclerosis | 31 |
south africa | 31 |
cell proliferation | 31 |
informed consent | 31 |
coronary artery | 31 |
focal segmental | 31 |
heart age | 31 |
care facilities | 31 |
metabolic acidosis | 31 |
upper respiratory | 31 |
data collected | 31 |
relative risk | 31 |
adaptive immunity | 31 |
confirmed cases | 30 |
immune cell | 30 |
well known | 30 |
one week | 30 |
human bocavirus | 30 |
cell senescence | 30 |
biopsy showed | 30 |
widely used | 30 |
second wave | 30 |
independently associated | 30 |
virus infection | 30 |
telomere length | 30 |
spatial indicators | 30 |
life course | 30 |
serum albumin | 30 |
survival rates | 30 |
infection fatality | 30 |
cause mortality | 30 |
health centre | 30 |
patients treated | 30 |
insulin resistance | 30 |
renal diseases | 30 |
artery disease | 30 |
transplant patients | 30 |
significant improvement | 30 |
better understand | 30 |
immunoglobulin replacement | 30 |
commonly used | 30 |
np swabs | 30 |
polio morbidity | 30 |
clinical studies | 30 |
odds ratios | 30 |
birth cohort | 30 |
disease severity | 30 |
future research | 29 |
per week | 29 |
weight gain | 29 |
disease progression | 29 |
acute phase | 29 |
case series | 29 |
common cause | 29 |
age related | 29 |
adverse outcomes | 29 |
literature review | 29 |
whole exome | 29 |
substance use | 29 |
cell cycle | 29 |
study period | 29 |
signaling pathway | 29 |
reactive protein | 29 |
study showed | 29 |
higher rates | 29 |
renal scarring | 29 |
health service | 29 |
one month | 29 |
urban health | 29 |
mg day | 29 |
cholesterol side | 29 |
inner city | 28 |
signaling pathways | 28 |
mortality risk | 28 |
medical history | 28 |
also associated | 28 |
gut microbiota | 28 |
urine samples | 28 |
mg protein | 28 |
reactive oxygen | 28 |
six patients | 28 |
cell lymphopenia | 28 |
pediatric intensive | 28 |
retrospective analysis | 28 |
older population | 28 |
study group | 28 |
mainland china | 28 |
mixing patterns | 28 |
epidemiological studies | 28 |
among elderly | 28 |
stress resilience | 28 |
eight patients | 28 |
transmission dynamics | 28 |
results showed | 28 |
less likely | 28 |
five patients | 28 |
patients receiving | 28 |
descriptive statistics | 28 |
cvid patients | 28 |
patients developed | 28 |
cell counts | 28 |
beneficial effects | 28 |
respiratory symptoms | 28 |
cells ul | 28 |
response rate | 28 |
social services | 27 |
vascular disease | 27 |
old mice | 27 |
will also | 27 |
study aimed | 27 |
cssa system | 27 |
medical care | 27 |
motor neuron | 27 |
protein excretion | 27 |
school closures | 27 |
primary health | 27 |
severe combined | 27 |
creatinine ratio | 27 |
analyzed using | 27 |
healthcare system | 27 |
electron microscopy | 27 |
among others | 27 |
autoimmune diseases | 27 |
living alone | 27 |
next generation | 27 |
elderly individuals | 27 |
lung injury | 27 |
viral load | 27 |
thymic involution | 27 |
computed tomography | 27 |
low dose | 27 |
younger people | 27 |
average number | 27 |
transcription factor | 27 |
mortality among | 26 |
young children | 26 |
body fat | 26 |
national institute | 26 |
advancing age | 26 |
health effects | 26 |
performance battery | 26 |
cell repertoire | 26 |
min mg | 26 |
multiple regression | 26 |
common variable | 26 |
elderly care | 26 |
older individuals | 26 |
type ii | 26 |
kidney transplant | 26 |
deaths per | 26 |
calorie restriction | 26 |
people living | 26 |
medical records | 26 |
dna methylation | 26 |
last years | 26 |
per patient | 26 |
human aging | 26 |
acute gastroenteritis | 26 |
care providers | 26 |
care needs | 26 |
mean follow | 26 |
regression analyses | 26 |
vesicoureteral reflux | 26 |
clinical symptoms | 26 |
aging research | 26 |
randomly selected | 26 |
organ failure | 26 |
cvd risk | 26 |
mental state | 26 |
amino acid | 26 |
street youth | 26 |
three times | 26 |
infection rates | 26 |
differential diagnosis | 26 |
hospitalized patients | 26 |
rural areas | 26 |
bacterial infections | 26 |
interstitial fibrosis | 26 |
significantly reduced | 25 |
data analysis | 25 |
chronic lung | 25 |
one study | 25 |
expectations regarding | 25 |
clinical diagnosis | 25 |
health professionals | 25 |
social frailty | 25 |
higher prevalence | 25 |
chronic pain | 25 |
will provide | 25 |
among community | 25 |
investigate whether | 25 |
birth year | 25 |
regarding aging | 25 |
colorectal cancer | 25 |
determined using | 25 |
control subjects | 25 |
fi rst | 25 |
younger patients | 25 |
health policy | 25 |
future studies | 25 |
risk groups | 25 |
pregnant women | 25 |
world studies | 25 |
social capital | 25 |
blood levels | 25 |
retrospective cohort | 25 |
mrna expression | 25 |
among children | 25 |
renal dysfunction | 25 |
outcome measures | 25 |
low physical | 25 |
renal involvement | 25 |
chronic inflammatory | 25 |
clinical research | 25 |
cancer patients | 25 |
patients died | 25 |
chart review | 25 |
blood mononuclear | 24 |
oxygen species | 24 |
public transport | 24 |
negative affect | 24 |
general hospital | 24 |
peer review | 24 |
significantly decreased | 24 |
ml kg | 24 |
protein expression | 24 |
waiting list | 24 |
transmission rate | 24 |
resonance imaging | 24 |
infected individuals | 24 |
muscle biopsy | 24 |
fatty acid | 24 |
natural killer | 24 |
blood cells | 24 |
social justice | 24 |
mouse model | 24 |
clinical outcomes | 24 |
south korea | 24 |
many countries | 24 |
short physical | 24 |
disease burden | 24 |
cell subsets | 24 |
per person | 24 |
study aims | 24 |
dietary intake | 24 |
antibody deficiency | 24 |
health survey | 24 |
grade inflammation | 24 |
mitochondrial dna | 24 |
patients may | 24 |
health education | 24 |
patients underwent | 24 |
five years | 24 |
income countries | 24 |
function tests | 24 |
paediatric patients | 24 |
key role | 24 |
reproduction number | 24 |
kidney function | 24 |
random sample | 24 |
first case | 24 |
high mortality | 23 |
slit diaphragm | 23 |
three different | 23 |
renal replacement | 23 |
symptomatic infectious | 23 |
health information | 23 |
influenza vaccine | 23 |
using data | 23 |
median follow | 23 |
paediatric neurology | 23 |
higher mortality | 23 |
muscle cells | 23 |
included studies | 23 |
baseline characteristics | 23 |
risk group | 23 |
prognostic factors | 23 |
private sector | 23 |
inflammatory mediators | 23 |
study sample | 23 |
time period | 23 |
social care | 23 |
high blood | 23 |
months old | 23 |
caloric restriction | 23 |
patients presented | 23 |
selenium deficiency | 23 |
significant reduction | 23 |
focus groups | 23 |
pd patients | 23 |
fat mass | 23 |
patient survival | 23 |
well tolerated | 23 |
soft tissue | 23 |
matched controls | 23 |
dent disease | 23 |
medical center | 23 |
missing data | 23 |
variable immunodeficiency | 23 |
million people | 23 |
high school | 23 |
patient group | 23 |
metabolic alkalosis | 23 |
liver transplant | 23 |
cox proportional | 23 |
older adult | 23 |
may explain | 23 |
mathematical model | 23 |
hospital admissions | 23 |
epidemic threshold | 23 |
patients presenting | 23 |
herpes zoster | 23 |
health issues | 23 |
death rate | 23 |
graft failure | 23 |
hazard ratio | 23 |
two different | 23 |
mitochondrial activity | 22 |
within days | 22 |
much lower | 22 |
african american | 22 |
vaccination coverage | 22 |
service delivery | 22 |
month period | 22 |
total protein | 22 |
first hours | 22 |
mean time | 22 |
mitochondrial biogenesis | 22 |
correlation coefficient | 22 |
demographic characteristics | 22 |
large number | 22 |
term outcome | 22 |
health research | 22 |
seven patients | 22 |
early stages | 22 |
early childhood | 22 |
consecutive patients | 22 |
inflammatory state | 22 |
rating scale | 22 |
cell activation | 22 |
social participation | 22 |
low income | 22 |
disease activity | 22 |
presentation will | 22 |
previously described | 22 |
dna damage | 22 |
urine culture | 22 |
growth retardation | 22 |
may reflect | 22 |
mechanically ventilated | 22 |
child health | 22 |
integrated care | 22 |
clinical phenotype | 22 |
cardiovascular events | 22 |
leading cause | 22 |
examination revealed | 22 |
posted may | 22 |
positive correlation | 22 |
differ significantly | 22 |
last year | 22 |
independent risk | 22 |
genes involved | 22 |
molecular mechanisms | 22 |
marital status | 22 |
epidemiological data | 22 |
subjective well | 22 |
necrosis factor | 22 |
cell exhaustion | 22 |
overall mortality | 22 |
nine patients | 22 |
lower limb | 22 |
western blot | 22 |
without controls | 22 |
calculated using | 22 |
observational study | 22 |
respiratory disease | 22 |
three groups | 22 |
data indicate | 22 |
first months | 22 |
ischemic stroke | 21 |
mg ml | 21 |
patients years | 21 |
first episode | 21 |
important risk | 21 |
dental caries | 21 |
showed normal | 21 |
normal renal | 21 |
underlying disease | 21 |
patient developed | 21 |
mechanisms underlying | 21 |
dna repair | 21 |
care units | 21 |
hiv positive | 21 |
alcohol use | 21 |
pension system | 21 |
may result | 21 |
cases per | 21 |
high incidence | 21 |
postmenopausal women | 21 |
infectious complications | 21 |
significant decrease | 21 |
creative commons | 21 |
evidence suggests | 21 |
incidence rates | 21 |
cell differentiation | 21 |
among adults | 21 |
diabetic patients | 21 |
cumulative number | 21 |
four years | 21 |
blood glucose | 21 |
skin cancer | 21 |
physical fitness | 21 |
successful aging | 21 |
control measures | 21 |
decision making | 21 |
yellow fever | 21 |
south asian | 21 |
signal transduction | 21 |
polio epidemic | 21 |
severe disease | 21 |
years later | 21 |
older person | 21 |
mobility disability | 21 |
sea peoples | 21 |
included patients | 21 |
minimal change | 21 |
significantly correlated | 21 |
perceived stress | 21 |
asymptomatic infectious | 21 |
low birth | 21 |
social media | 21 |
inflammatory markers | 21 |
study shows | 21 |
multivariate logistic | 21 |
health literacy | 21 |
streptococcus pneumoniae | 21 |
related disease | 20 |
reproductive number | 20 |
positive patients | 20 |
premature infants | 20 |
old individuals | 20 |
will need | 20 |
small number | 20 |
social networks | 20 |
ormond street | 20 |
data sets | 20 |
negative impact | 20 |
newborn screening | 20 |
year age | 20 |
increased susceptibility | 20 |
months post | 20 |
vaccination strategies | 20 |
year survival | 20 |
intravenous immunoglobulin | 20 |
many studies | 20 |
closely related | 20 |
cell development | 20 |
chronic stress | 20 |
inflammasome activation | 20 |
uremic syndrome | 20 |
native dutch | 20 |
patients older | 20 |
ray absorptiometry | 20 |
healthy subjects | 20 |
acute pyelonephritis | 20 |
system capacity | 20 |
neurological examination | 20 |
healthy older | 20 |
chronic low | 20 |
heterozygous mutations | 20 |
respiratory diseases | 20 |
service providers | 20 |
cohort studies | 20 |
urban poor | 20 |
old people | 20 |
great ormond | 20 |
greater risk | 20 |
persons aged | 20 |
important factor | 20 |
saharan africa | 20 |
lifestyle factors | 20 |
normal controls | 20 |
systolic blood | 20 |
lung diseases | 20 |
research center | 20 |
cancer registry | 20 |
may affect | 20 |
dialysis patients | 20 |
visual outcomes | 20 |
major risk | 20 |
healthcare professionals | 20 |
per min | 20 |
analysis revealed | 20 |
arterial blood | 20 |
usual care | 20 |
immune functions | 20 |
hearing loss | 20 |
range proteinuria | 20 |
significant risk | 20 |
elderly subjects | 20 |
health problem | 20 |
critical role | 20 |
poor outcome | 20 |
early life | 19 |
carotid artery | 19 |
cell carcinoma | 19 |
frailty among | 19 |
inflammatory cytokine | 19 |
estimated using | 19 |
lower respiratory | 19 |
total cholesterol | 19 |
work ability | 19 |
labor market | 19 |
positive cells | 19 |
steroid resistant | 19 |
angiotensin converting | 19 |
living standards | 19 |
higher incidence | 19 |
smoking cessation | 19 |
age category | 19 |
one child | 19 |
primary outcome | 19 |
american neurological | 19 |
significantly improved | 19 |
study conducted | 19 |
retrospective review | 19 |
protein levels | 19 |
nuclear factor | 19 |
authors declare | 19 |
term survival | 19 |
viral replication | 19 |
randomized clinical | 19 |
ill children | 19 |
better understanding | 19 |
many cases | 19 |
patient presented | 19 |
infectious individuals | 19 |
neurodegenerative diseases | 19 |
severe cases | 19 |
general practice | 19 |
remained stable | 19 |
case presentation | 19 |
organ transplantation | 19 |
lifespan development | 19 |
diastolic blood | 19 |
sexually transmitted | 19 |
time point | 19 |
aged individuals | 19 |
antibody response | 19 |
past years | 19 |
sensitivity analysis | 19 |
neurological association | 19 |
beneficial effect | 19 |
one hundred | 19 |
comprehensive geriatric | 19 |
health conditions | 19 |
monoclonal antibodies | 19 |
chronic allograft | 19 |
resistance training | 19 |
randomised controlled | 19 |
healthy elderly | 19 |
elderly asthmatic | 19 |
many patients | 19 |
cerebrospinal fluid | 19 |
ckd stage | 19 |
congenital heart | 19 |
genetic analysis | 19 |
european working | 19 |
microscopic hematuria | 19 |
trough levels | 19 |
will help | 19 |
univariate analysis | 19 |
population health | 19 |
serial interval | 19 |
risk assessment | 19 |
seizure frequency | 19 |
research team | 19 |
protein synthesis | 19 |
infected patients | 19 |
renal damage | 19 |
retirement age | 18 |
may represent | 18 |
vascular risk | 18 |
primary immune | 18 |
cell transplant | 18 |
oral health | 18 |
damaged mitochondria | 18 |
angiotensin ii | 18 |
assisted living | 18 |
higher among | 18 |
nephrotic range | 18 |
studies suggest | 18 |
ad patients | 18 |
immunosuppressive therapy | 18 |
influenza virus | 18 |
cumulative incidence | 18 |
mental status | 18 |
fold increase | 18 |
tissue damage | 18 |
age structure | 18 |
future directions | 18 |
central role | 18 |
social class | 18 |
medrxiv preprint | 18 |
focus group | 18 |
cross sectional | 18 |
gene mutation | 18 |
gene encoding | 18 |
arterial hypertension | 18 |
ethnic minority | 18 |
gold standard | 18 |
differentially expressed | 18 |
health behaviors | 18 |
patients whose | 18 |
energy intake | 18 |
study demonstrates | 18 |
poor health | 18 |
frailty screening | 18 |
renal impairment | 18 |
high dose | 18 |
prospective studies | 18 |
secretory phenotype | 18 |
disease onset | 18 |
san francisco | 18 |
amyotrophic lateral | 18 |
health systems | 18 |
adult population | 18 |
lipid profile | 18 |
enzyme activity | 18 |
paediatric intensive | 18 |
kidney biopsy | 18 |
young copd | 18 |
hospital stay | 18 |
late bronze | 18 |
significant change | 18 |
cell lines | 18 |
urine protein | 18 |
harm reduction | 18 |
plasma exchange | 18 |
longitudinal studies | 18 |
sarcopenic obesity | 18 |
significantly greater | 18 |
lymph node | 18 |
likely due | 18 |
three years | 18 |
ageing society | 18 |
sex differences | 18 |
incidence rate | 18 |
survival rate | 18 |
different countries | 18 |
emergency departments | 18 |
ct scan | 18 |
within months | 18 |
aged mice | 18 |
street hospital | 18 |
humoral immunity | 18 |
educational level | 18 |
wild type | 18 |
recent study | 18 |
geriatric assessment | 18 |
nutritional support | 18 |
demographic information | 18 |
old rats | 18 |
individuals aged | 18 |
reserve capacity | 18 |
airway inflammation | 18 |
cell line | 18 |
angiotensin system | 18 |
showed significant | 18 |
hospital admission | 18 |
may influence | 18 |
cell count | 18 |
myeloid cell | 18 |
opportunistic infections | 18 |
increased expression | 18 |
clinical information | 18 |
lateral sclerosis | 18 |
influenza pandemic | 18 |
substance abuse | 18 |
previous research | 18 |
may reduce | 18 |
newly diagnosed | 18 |
polyunsaturated fatty | 17 |
alkaline phosphatase | 17 |
dysfunctional mitochondria | 17 |
screening tool | 17 |
specific antibody | 17 |
affected individuals | 17 |
related mortality | 17 |
aging processes | 17 |
similar results | 17 |
middle east | 17 |
general health | 17 |
influenza vaccines | 17 |
social contact | 17 |
nerve conduction | 17 |
developed countries | 17 |
main cause | 17 |
across different | 17 |
adverse health | 17 |
heat shock | 17 |
nephritic syndrome | 17 |
successfully treated | 17 |
related decline | 17 |
patient characteristics | 17 |
may occur | 17 |
ischemic heart | 17 |
overall survival | 17 |
basement membrane | 17 |
may increase | 17 |
protein kinase | 17 |
mouse models | 17 |
study will | 17 |
zinc ion | 17 |
mitochondrial health | 17 |
status epilepticus | 17 |
th day | 17 |
group compared | 17 |
increased significantly | 17 |
research project | 17 |
grade iii | 17 |
ethnic groups | 17 |
statistical analyses | 17 |
gender differences | 17 |
potential role | 17 |
disease transmission | 17 |
patients referred | 17 |
cancer screening | 17 |
organ damage | 17 |
hemolytic uremic | 17 |
individual level | 17 |
immune activation | 17 |
generation sequencing | 17 |
mediterranean diet | 17 |
hittite empire | 17 |
particularly important | 17 |
cells may | 17 |
endoplasmic reticulum | 17 |
data sources | 17 |
creatinine level | 17 |
related differences | 17 |
frail elderly | 17 |
lymph nodes | 17 |
poisson regression | 17 |
muscle quality | 17 |
frailty phenotype | 17 |
also known | 17 |
increased levels | 17 |
pediatric renal | 17 |
major role | 17 |
lupus erythematosus | 17 |
ejection fraction | 17 |
mitochondrial turnover | 17 |
among people | 17 |
communicable diseases | 17 |
population ageing | 17 |
outpatient clinic | 17 |
clinical examination | 17 |
first years | 17 |
higher rate | 17 |
case study | 17 |
different ages | 17 |
informal care | 17 |
two main | 17 |
renal survival | 17 |
case reports | 17 |
prostate cancer | 17 |
one hand | 17 |
aerobic glycolysis | 17 |
drinking water | 17 |
two decades | 17 |
lowe syndrome | 17 |
inversely associated | 17 |
per month | 17 |
economic status | 17 |
weeks gestation | 17 |
partial remission | 17 |
among men | 17 |
disease prevention | 17 |
lymphoid cells | 17 |
will likely | 17 |
treatment group | 17 |
liver function | 17 |
frail women | 17 |
period effects | 16 |
viral hepatitis | 16 |
liver biopsy | 16 |
like receptor | 16 |
vaccine development | 16 |
positively associated | 16 |
nicotinamide riboside | 16 |
health benefits | 16 |
kidney diseases | 16 |
survival analysis | 16 |
salt wasting | 16 |
syncytial virus | 16 |
steroid sensitive | 16 |
cx cl | 16 |
patients undergoing | 16 |
sexual health | 16 |
csa treatment | 16 |
food insecurity | 16 |
epidemiologic studies | 16 |
right place | 16 |
cmv infection | 16 |
combined therapy | 16 |
liver failure | 16 |
sedentary behavior | 16 |
one third | 16 |
preterm infants | 16 |
high doses | 16 |
living conditions | 16 |
chair stand | 16 |
baseline va | 16 |
medical science | 16 |
homozygous mutation | 16 |
neurological symptoms | 16 |
negative correlation | 16 |
patients infected | 16 |
related quality | 16 |
rheumatoid arthritis | 16 |
mitochondrial dynamics | 16 |
cell aging | 16 |
study provides | 16 |
renal artery | 16 |
congestive heart | 16 |
septic shock | 16 |
lipid peroxidation | 16 |
nutritional assessment | 16 |
tubular function | 16 |
mean arterial | 16 |
bone density | 16 |
cerebrovascular disease | 16 |
trace elements | 16 |
biopsy specimens | 16 |
groups according | 16 |
lower extremity | 16 |
unintentional weight | 16 |
proximal tubular | 16 |
infection control | 16 |
neonatal period | 16 |
symptom onset | 16 |
also showed | 16 |
epidemiological characteristics | 16 |
older populations | 16 |
increased mortality | 16 |
years ago | 16 |
arterial stiffness | 16 |
reported symptomatic | 16 |
many older | 16 |
patient data | 16 |
visual acuity | 16 |
myeloid cells | 16 |
target population | 16 |
last months | 16 |
markov chain | 16 |
vascular smooth | 16 |
cell type | 16 |
high frequency | 16 |
study included | 16 |
oral prednisone | 16 |
year mortality | 16 |
mean scores | 16 |
proportional hazards | 16 |
copd patients | 16 |
modelling study | 16 |
poor prognosis | 16 |
allograft nephropathy | 16 |
growth hormone | 16 |
zoster virus | 16 |
studies showed | 16 |
arterial pressure | 16 |
financial situation | 16 |
elevated levels | 16 |
old woman | 16 |
mycobacterium tuberculosis | 16 |
global health | 16 |
increased incidence | 16 |
central venous | 16 |
cell numbers | 16 |
mental retardation | 16 |
muscle wasting | 16 |
idiopathic nephrotic | 16 |
lean mass | 16 |
tubular atrophy | 16 |
key factor | 16 |
observational studies | 16 |
respiratory function | 16 |
mean number | 16 |
different types | 16 |
public sector | 16 |
age matched | 16 |
potential confounders | 16 |
will allow | 16 |
patients will | 16 |
extracellular matrix | 16 |
aging population | 16 |
cell surface | 16 |
middle age | 16 |
tumor necrosis | 16 |
women living | 16 |
cardiac output | 16 |
cerebral palsy | 16 |
strongly associated | 16 |
mutant mice | 16 |
will discuss | 16 |
serum concentrations | 16 |
epidemiological research | 16 |
social factors | 16 |
important cause | 16 |
exclusion criteria | 16 |
preventive measures | 16 |
geriatric syndromes | 16 |
airway obstruction | 16 |
first step | 16 |
ige levels | 16 |
brain injury | 16 |
time points | 16 |
submission id | 16 |
days later | 16 |
last follow | 16 |
mononuclear cell | 15 |
many people | 15 |
inflammatory process | 15 |
psychological stress | 15 |
missense mutation | 15 |
lower risk | 15 |
transcript levels | 15 |
respiratory system | 15 |
showed higher | 15 |
related chronic | 15 |
analysed using | 15 |
decision tree | 15 |
cd cell | 15 |
square test | 15 |
united nations | 15 |
zinc deficiency | 15 |
cancer mortality | 15 |
near future | 15 |
also increased | 15 |
viral respiratory | 15 |
patient groups | 15 |
flow cytometric | 15 |
past decade | 15 |
girl presented | 15 |
second phase | 15 |
bacterial infection | 15 |
step life | 15 |
analysis using | 15 |
allow us | 15 |
renal functions | 15 |
three children | 15 |
muscle quantity | 15 |
public open | 15 |
supplementary section | 15 |
inflammatory disease | 15 |
scoping review | 15 |
roc curve | 15 |
risk patients | 15 |
patient population | 15 |
venous blood | 15 |
blood cell | 15 |
labour force | 15 |
transmission rates | 15 |
urban settings | 15 |
immune senescence | 15 |
average time | 15 |
renal scars | 15 |
health interventions | 15 |
skin lesions | 15 |
role played | 15 |
abdominal obesity | 15 |
inborn errors | 15 |
resistant nephrotic | 15 |
especially important | 15 |
main risk | 15 |
duffy null | 15 |
community services | 15 |
longitudinal data | 15 |
sample sizes | 15 |
elderly men | 15 |
systemic lupus | 15 |
heart transplantation | 15 |
light microscopy | 15 |
early stage | 15 |
pulmonary fibrosis | 15 |
glomerular disease | 15 |
study suggests | 15 |
per se | 15 |
prevalence rates | 15 |
respiratory syncytial | 15 |
several years | 15 |
social determinants | 15 |
significant effect | 15 |
labor force | 15 |
calcineurin inhibitor | 15 |
dengue virus | 15 |
based research | 15 |
population based | 15 |
critical care | 15 |
one another | 15 |
previous reports | 15 |
aerobic exercise | 15 |
across countries | 15 |
mental illness | 15 |
treated patients | 15 |
study examined | 15 |
medical treatment | 15 |
often associated | 15 |
muscle thickness | 15 |
several factors | 15 |
lung infection | 15 |
geriatric medicine | 15 |
chronic conditions | 15 |
renal tissue | 15 |
hemolytic anemia | 15 |
vascular resistance | 15 |
sppb score | 15 |
healthcare services | 15 |
human rights | 15 |
general practitioners | 15 |
blood gases | 15 |
interstitial nephritis | 15 |
data will | 15 |
urinary excretion | 15 |
positive cases | 15 |
taken together | 15 |
antibody production | 15 |
low grade | 15 |
heterozygous mutation | 15 |
renal allograft | 15 |
median duration | 15 |
clinical evidence | 15 |
low serum | 15 |
frail individuals | 15 |
pao fio | 15 |
motor function | 15 |
mental disorders | 15 |
also significantly | 15 |
ex vivo | 15 |
child development | 15 |
prism score | 15 |
pathogenic variants | 15 |
oxidative damage | 15 |
gastrointestinal tract | 15 |
fold increased | 15 |
preliminary data | 15 |
generational groups | 15 |
screening programme | 15 |
per capita | 15 |
broad spectrum | 15 |
granulomatous disease | 15 |
energy expenditure | 15 |
remains unclear | 15 |
mri showed | 15 |
exercise program | 15 |
among young | 15 |
epigenetic changes | 15 |
first days | 15 |
exact test | 15 |
elderly patient | 15 |
clinical picture | 15 |
patient age | 15 |
instrumental activities | 15 |
great deal | 15 |
group patients | 15 |
showed significantly | 15 |
adults may | 15 |
national center | 15 |
older asthmatic | 15 |
los angeles | 15 |
weeks later | 15 |
supplementary table | 15 |
community members | 15 |
disease risk | 15 |
antibiotic therapy | 15 |
across multiple | 15 |
like growth | 15 |
platelet count | 15 |
high quality | 15 |
vaccine efficacy | 15 |
deficient patients | 15 |
also used | 15 |
geriatric syndrome | 15 |
correlation coefficients | 15 |
take care | 14 |
risk communication | 14 |
cell response | 14 |
relatively low | 14 |
chronic respiratory | 14 |
smoking status | 14 |
infant mortality | 14 |
vertical confinement | 14 |
local community | 14 |
growth failure | 14 |
urinary nag | 14 |
aging study | 14 |
social relationships | 14 |
patients compared | 14 |
autoimmune disease | 14 |
matter lesions | 14 |
report two | 14 |
life insurance | 14 |
post transplant | 14 |
african americans | 14 |
frailty syndrome | 14 |
metabolic disorders | 14 |
pivotal role | 14 |
domestic dogs | 14 |
local health | 14 |
lower levels | 14 |
case numbers | 14 |
successful ageing | 14 |
old man | 14 |
ageing population | 14 |
older ages | 14 |
patients diagnosed | 14 |
cultured cells | 14 |
irish journal | 14 |
studies indicate | 14 |
health study | 14 |
asthma control | 14 |
intracellular zinc | 14 |
data available | 14 |
urinary incontinence | 14 |
lymphocyte subsets | 14 |
group included | 14 |
primary vur | 14 |
evoked potentials | 14 |
st century | 14 |
innate lymphoid | 14 |
will increase | 14 |
paper will | 14 |
treatment regimens | 14 |
induction therapy | 14 |
healthy individuals | 14 |
young age | 14 |
evaluated using | 14 |
mosm kg | 14 |
will continue | 14 |
assess whether | 14 |
risk profile | 14 |
selection bias | 14 |
allostatic load | 14 |
icu admission | 14 |
recent advances | 14 |
within normal | 14 |
functional disability | 14 |
skin biopsy | 14 |
remained unchanged | 14 |
state examination | 14 |
among age | 14 |
economic conditions | 14 |
barthel index | 14 |
every weeks | 14 |
homeless people | 14 |
research questions | 14 |
cancer cases | 14 |
intervention program | 14 |
vur grade | 14 |
healthy control | 14 |
healthcare providers | 14 |
colon cancer | 14 |
pediatric population | 14 |
tubular cells | 14 |
mg daily | 14 |
examination showed | 14 |
genetic factors | 14 |
old patients | 14 |
i interferon | 14 |
massage therapy | 14 |
children received | 14 |
adverse reactions | 14 |
cell lymphoma | 14 |
degenerative joint | 14 |
literature search | 14 |
back pain | 14 |
symptomatic infections | 14 |
family member | 14 |
nphs mutations | 14 |
otitis media | 14 |
disease course | 14 |
first week | 14 |
across age | 14 |
observed among | 14 |
showed increased | 14 |
muscle protein | 14 |
immune changes | 14 |
may cause | 14 |
negative self | 14 |
grade i | 14 |
creatinine levels | 14 |
zinc release | 14 |
copy number | 14 |
another important | 14 |
participants completed | 14 |
progressive renal | 14 |
severe renal | 14 |
short term | 14 |
first report | 14 |
ketogenic diet | 14 |
see table | 14 |
related disorders | 14 |
antibody titers | 14 |
human coronaviruses | 14 |
cd ra | 14 |
waist circumference | 14 |
frail patients | 14 |
cells mcl | 14 |
medical conditions | 14 |
security system | 14 |
lower urinary | 14 |
service provision | 14 |
social contacts | 14 |
policy makers | 14 |
calcium excretion | 14 |
eastern europe | 14 |
significant negative | 14 |
crucial role | 14 |
previously healthy | 14 |
complex i | 14 |
laboratory data | 14 |
sars coronavirus | 14 |
lower limbs | 14 |
psychosocial factors | 14 |
intracranial hypertension | 14 |
serious infections | 14 |
grade vur | 14 |
still unclear | 14 |
nphs gene | 14 |
body size | 14 |
higher scores | 14 |
uk objective | 14 |
insulin sensitivity | 14 |
inflammatory effects | 14 |
neurological disorders | 14 |
head injury | 14 |
therapeutic strategies | 14 |
associated diseases | 14 |
death rates | 14 |
metabolic diseases | 14 |
infectious agents | 13 |
memory cd | 13 |
therapeutic intervention | 13 |
evidence indicates | 13 |
least two | 13 |
first reported | 13 |
defined using | 13 |
pulmonary vascular | 13 |
normal aging | 13 |
structured model | 13 |
social life | 13 |
complement activation | 13 |
whole blood | 13 |
diffuse mesangial | 13 |
aging labour | 13 |
lived environments | 13 |
major cause | 13 |
specific age | 13 |
vascular diseases | 13 |
health indicators | 13 |
effective treatment | 13 |
movement disorders | 13 |
movement disorder | 13 |
test results | 13 |
significantly related | 13 |
dock deficiency | 13 |
passive smoking | 13 |
participants also | 13 |
related health | 13 |
uk real | 13 |
general practitioner | 13 |
time spent | 13 |
ethnic minorities | 13 |
dm patients | 13 |
time pcr | 13 |
primary disease | 13 |
school year | 13 |
muscle fibers | 13 |
groups based | 13 |
parenteral nutrition | 13 |
will lead | 13 |
promote healthy | 13 |
tubular dysfunction | 13 |
phase i | 13 |
may improve | 13 |
evaluate whether | 13 |
public policy | 13 |
first wave | 13 |
flow rate | 13 |
animal studies | 13 |
steroid treatment | 13 |
neurological diseases | 13 |
fixed effects | 13 |
inflammatory status | 13 |
increased production | 13 |
atrial fibrillation | 13 |
teaching hospital | 13 |
data show | 13 |
white blood | 13 |
renal ultrasound | 13 |
healthy adults | 13 |
intermittent fasting | 13 |
available data | 13 |
class ii | 13 |
mammalian target | 13 |
highly significant | 13 |
expression patterns | 13 |
single cell | 13 |
seizure onset | 13 |
hand grip | 13 |
cox regression | 13 |
every year | 13 |
well established | 13 |
statistical methods | 13 |
vascular endothelial | 13 |
mean difference | 13 |
increased prevalence | 13 |
collected data | 13 |
fanconi syndrome | 13 |
sleep quality | 13 |
mm hg | 13 |
early onset | 13 |
relapse rate | 13 |
attack rate | 13 |
mhc class | 13 |
older recipients | 13 |
dependent manner | 13 |
clinical management | 13 |
high rate | 13 |
stand test | 13 |
real time | 13 |
ms patients | 13 |
clinical study | 13 |
airway pressure | 13 |
time series | 13 |
rudolph zacher | 13 |
financial crisis | 13 |
child poverty | 13 |
cord blood | 13 |
crp levels | 13 |
male sex | 13 |
cancer incidence | 13 |
study found | 13 |
infected cases | 13 |
inflammatory diseases | 13 |
significant impact | 13 |
asian msm | 13 |
high glucose | 13 |
open access | 13 |
antigen presentation | 13 |
multivariate analyses | 13 |
individual differences | 13 |
children admitted | 13 |
vast majority | 13 |
reticulum stress | 13 |
developed severe | 13 |
human development | 13 |
mean score | 13 |
kg min | 13 |
laboratory findings | 13 |
health related | 13 |
failure due | 13 |
serum calcium | 13 |
urban communities | 13 |
increasing number | 13 |
infected children | 13 |
aging immune | 13 |
host response | 13 |
give rise | 13 |
copd group | 13 |
stress responses | 13 |
cultural groups | 13 |
significant correlations | 13 |
normal levels | 13 |
exercise training | 13 |
cells mm | 13 |
medication use | 13 |
infected people | 13 |
surveillance system | 13 |
positively correlated | 13 |
drug abuse | 13 |
serum uric | 13 |
medical services | 13 |
chronic granulomatous | 13 |
intrauterine growth | 13 |
serious adverse | 13 |
acute myocardial | 13 |
graft loss | 13 |
children presenting | 13 |
functional studies | 13 |
laboratory tests | 13 |
pulmonary artery | 13 |
adjusted cfrs | 13 |
pulmonary tuberculosis | 13 |
global burden | 13 |
retrospectively reviewed | 13 |
motor neurons | 13 |
elderly women | 13 |
binding protein | 13 |
rare disease | 13 |
qualitative study | 13 |
new onset | 13 |
clinically relevant | 13 |
severe asthma | 13 |
adverse effect | 13 |
macroscopic hematuria | 13 |
pulse therapy | 13 |
normal values | 13 |
group differences | 13 |
diabetic nephropathy | 13 |
uncertain significance | 13 |
past year | 13 |
asthma exacerbations | 13 |
inflammatory responses | 13 |
care systems | 13 |
relative survival | 13 |
monoclonal antibody | 13 |
endotracheal intubation | 13 |
evolutionary perspective | 13 |
adults undergoing | 13 |
disease caused | 13 |
vaccine response | 13 |
urinary ph | 13 |
lung inflammation | 13 |
egfr sch | 13 |
potential therapeutic | 13 |
sensory loss | 13 |
injection drug | 13 |
iron age | 13 |
inflammatory processes | 13 |
east respiratory | 13 |
multiple organ | 13 |
recurrent uti | 13 |
two age | 13 |
examine whether | 13 |
rates among | 13 |
personal resources | 13 |
first line | 13 |
lower incidence | 13 |
initial presentation | 13 |
joint disease | 13 |
cigarette smoking | 13 |
icu syndrome | 13 |
drug treatment | 13 |
lean body | 13 |
trough level | 13 |
clinical evaluation | 13 |
life events | 13 |
appendicular skeletal | 13 |
immunosuppressive treatment | 13 |
retrospective chart | 13 |
pathogenic variant | 13 |
immune complex | 13 |
pediatric icu | 12 |
respiratory infection | 12 |
infections among | 12 |
control policies | 12 |
gene polymorphism | 12 |
transmitted diseases | 12 |
virus infections | 12 |
negative effects | 12 |
human immune | 12 |
following criteria | 12 |
much less | 12 |
factors influencing | 12 |
aged rats | 12 |
intravitreal ranibizumab | 12 |
cigarette smoke | 12 |
specific health | 12 |
food intake | 12 |
text messages | 12 |
working age | 12 |
surgical procedures | 12 |
surveillance systems | 12 |
consanguineous parents | 12 |
compared using | 12 |
measles transmissions | 12 |
tcr repertoire | 12 |
major causes | 12 |
acute coronary | 12 |
standard errors | 12 |
primary immunodeficiencies | 12 |
smokers vs | 12 |
heavy proteinuria | 12 |
also examined | 12 |
health behavior | 12 |
also performed | 12 |
positive family | 12 |
also reported | 12 |
studies using | 12 |
basal ganglia | 12 |
raw data | 12 |
high rates | 12 |
recurrent episodes | 12 |
urinary calcium | 12 |
results demonstrate | 12 |
term prognosis | 12 |
overall health | 12 |
direct sequencing | 12 |
provide evidence | 12 |
current research | 12 |
fully understood | 12 |
blood count | 12 |
physical inactivity | 12 |
outcomes among | 12 |
resistance exercise | 12 |
participants aged | 12 |
low education | 12 |
two months | 12 |
cognitive functions | 12 |
treatment options | 12 |
studied patients | 12 |
associated secretory | 12 |
term effects | 12 |
activity level | 12 |
blood urea | 12 |
significant improvements | 12 |
spike protein | 12 |
age may | 12 |
lipid rafts | 12 |
proportional hazard | 12 |
care workers | 12 |
biopsy proven | 12 |
studies will | 12 |
global pandemic | 12 |
enzyme inhibitors | 12 |
plasma levels | 12 |
poorly understood | 12 |
physical functioning | 12 |
specific ige | 12 |
sedentary time | 12 |
per age | 12 |
improved significantly | 12 |
upper limb | 12 |
novel mutation | 12 |
seven countries | 12 |
patient died | 12 |
health disparities | 12 |
generational research | 12 |
introduction background | 12 |
safety profile | 12 |
mediated immunity | 12 |
without significant | 12 |
frozen plasma | 12 |
lifestyle interventions | 12 |
group pathogens | 12 |
health risks | 12 |
oral cyclophosphamide | 12 |
connective tissue | 12 |
inflammatory pathways | 12 |
take place | 12 |
higher number | 12 |
copa syndrome | 12 |
absolute number | 12 |
associated factors | 12 |
bone formation | 12 |
ros production | 12 |
many factors | 12 |
diagnostic tests | 12 |
tertiary care | 12 |
influenza infection | 12 |
clinical findings | 12 |
results will | 12 |
investigated whether | 12 |
afc spatial | 12 |
least months | 12 |
many different | 12 |
mitochondrial cytochrome | 12 |
different groups | 12 |
disease duration | 12 |
year later | 12 |
retrospective case | 12 |
intellectual disability | 12 |
airflow obstruction | 12 |
bone mineral | 12 |
four months | 12 |
human health | 12 |
endothelial cell | 12 |
depression scale | 12 |
children living | 12 |
lipid metabolism | 12 |
cardiac arrest | 12 |
associated changes | 12 |
ten years | 12 |
renal development | 12 |
also measured | 12 |
fresh frozen | 12 |
i will | 12 |
may present | 12 |
mesangial cells | 12 |
chinese population | 12 |
adjusted odds | 12 |
showed mild | 12 |
low level | 12 |
based medicine | 12 |
protective role | 12 |
severe respiratory | 12 |
western countries | 12 |
age structured | 12 |
grounded theory | 12 |
community dwelling | 12 |
mutational analysis | 12 |
healthy volunteers | 12 |
tubular acidosis | 12 |
gender estimation | 12 |
serum total | 12 |
immunosuppressive drugs | 12 |
public intervention | 12 |
inflammatory activity | 12 |
surface expression | 12 |
cleavage activity | 12 |
might also | 12 |
antibody responses | 12 |
host factors | 12 |
muscular dystrophy | 12 |
capacity building | 12 |
based participatory | 12 |
collagen type | 12 |
ill patients | 12 |
control strategies | 12 |
independent living | 12 |
old subjects | 12 |
arterial disease | 12 |
initial evaluation | 12 |
birth cohorts | 12 |
vessel vasculitis | 12 |
many years | 12 |
national institutes | 12 |
based study | 12 |
rs virus | 12 |
aged adults | 12 |
will focus | 12 |
wilms tumor | 12 |
dry weight | 12 |
modulate mitochondrial | 12 |
young non | 12 |
mesangial proliferation | 12 |
medical management | 12 |
red blood | 12 |
study also | 12 |
related atherosclerosis | 12 |
gyeonggi province | 12 |
might lead | 12 |
female ratio | 12 |
old copd | 12 |
data set | 12 |
immunoglobulin levels | 12 |
friendly cities | 12 |
long time | 12 |
new patients | 12 |
may well | 12 |
polycystic kidney | 12 |
health consequences | 12 |
gfr ml | 12 |
older children | 12 |
upper airway | 12 |
reference cohort | 12 |
postoperative complications | 12 |
without evidence | 12 |
spastic paraparesis | 12 |
related loss | 12 |
healthy lifestyle | 12 |
support services | 12 |
partly due | 12 |
treatment strategies | 12 |
latin american | 12 |
mean dose | 12 |
intrinsic capacity | 12 |
incidence among | 12 |
also observed | 12 |
resource utilization | 12 |
schwartz formula | 12 |
aging lung | 12 |
elderly adults | 12 |
may prevent | 12 |
cognitive performance | 12 |
hiv disease | 12 |
clinical immunology | 12 |
ureteric bud | 11 |
diseases including | 11 |
serum samples | 11 |
transplant candidates | 11 |
unclear whether | 11 |
relatively high | 11 |
surveillance data | 11 |
another study | 11 |
allergic diseases | 11 |
activated protein | 11 |
patient education | 11 |
financial support | 11 |
single centre | 11 |
muscle volume | 11 |
endothelial growth | 11 |
studies show | 11 |
functional outcome | 11 |
may differ | 11 |
signalling pathway | 11 |
positive predictive | 11 |
daughter caring | 11 |
communitydwelling older | 11 |
emerging evidence | 11 |
low risk | 11 |
aged people | 11 |
bartter syndrome | 11 |
childhood cancer | 11 |
study indicated | 11 |
department visits | 11 |
housing affordability | 11 |
recent data | 11 |
wide resnet | 11 |
dawley rats | 11 |
obstructive uropathy | 11 |
also evaluated | 11 |
organ dysfunction | 11 |
ethics committee | 11 |
systematic reviews | 11 |
table shows | 11 |
skin test | 11 |
population aging | 11 |
interquartile range | 11 |
diabetes patients | 11 |
studies reported | 11 |
acute stress | 11 |
inflammatory profile | 11 |
thrombotic microangiopathy | 11 |
anthropometric measurements | 11 |
significant clinical | 11 |
will include | 11 |
chronic infection | 11 |
gray matter | 11 |
th cells | 11 |
accelerated aging | 11 |
commons attribution | 11 |
van der | 11 |
cardiac transplantation | 11 |
early phase | 11 |
negative outcomes | 11 |
essential hypertension | 11 |
cell culture | 11 |
sex hormones | 11 |
frail scale | 11 |
propensity score | 11 |
transplanted patients | 11 |
age distributions | 11 |
missense mutations | 11 |
copd subjects | 11 |
routine clinical | 11 |
igd igm | 11 |
primary prevention | 11 |
barr virus | 11 |
degree relatives | 11 |
group received | 11 |
gender difference | 11 |
adults living | 11 |
female patients | 11 |
comorbid conditions | 11 |
normal blood | 11 |
sensitive nephrotic | 11 |
antihypertensive drugs | 11 |
kong government | 11 |
analysis included | 11 |
steroid withdrawal | 11 |
cognitive aging | 11 |
gastroenteritis viruses | 11 |
twelve patients | 11 |
showed similar | 11 |
renal stones | 11 |
cardiovascular health | 11 |
common among | 11 |
subjects aged | 11 |
quadriceps muscle | 11 |
cd ro | 11 |
entering approach | 11 |
steroid resistance | 11 |
obese older | 11 |
calcineurin inhibitors | 11 |
research process | 11 |
based case | 11 |
conservative treatment | 11 |
reproductive health | 11 |
sustainable development | 11 |
twice daily | 11 |
young patients | 11 |
common diseases | 11 |
economic factors | 11 |
severely affected | 11 |
cr ratio | 11 |
hd patients | 11 |
wide variety | 11 |
sarcopenic older | 11 |
royal manchester | 11 |
multicenter study | 11 |
perspective offers | 11 |
pain relief | 11 |
agerelated diseases | 11 |
baseline data | 11 |
patients also | 11 |
higher probability | 11 |
age cohorts | 11 |
least years | 11 |
primary healthcare | 11 |
rate variability | 11 |
venous thrombosis | 11 |
unreported cases | 11 |
social exclusion | 11 |
older veterans | 11 |
around age | 11 |
endothelial dysfunction | 11 |
basic reproduction | 11 |
primary endpoint | 11 |
gene therapy | 11 |
statistical difference | 11 |
mitochondrial stress | 11 |
progressive loss | 11 |
mini nutritional | 11 |
outcome data | 11 |
acute lung | 11 |
daily life | 11 |
incubation period | 11 |
design methods | 11 |
modifiable risk | 11 |
coronavirus infection | 11 |
throughout life | 11 |
icu stay | 11 |
will contribute | 11 |
generational thinking | 11 |
intervention studies | 11 |
bone turnover | 11 |
protective effects | 11 |
tissue injury | 11 |
patients hospitalized | 11 |
age differences | 11 |
term outcomes | 11 |
single dose | 11 |
larger number | 11 |
brachial plexus | 11 |
social inclusion | 11 |
renal injury | 11 |
physical functions | 11 |
immunodeficiency virus | 11 |
ang ii | 11 |
positive association | 11 |
autoimmune cytopenias | 11 |
drug therapy | 11 |
deficient mice | 11 |
varicella zoster | 11 |
cardiovascular system | 11 |
urea nitrogen | 11 |
ventricular hypertrophy | 11 |
rhgh therapy | 11 |
human coronavirus | 11 |
times higher | 11 |
muscle contraction | 11 |
telomerase activity | 11 |
significant morbidity | 11 |
normal population | 11 |
related factors | 11 |
elevated serum | 11 |
stress response | 11 |
crb tbr | 11 |
fi nancial | 11 |
i i | 11 |
high degree | 11 |
young adult | 11 |
people may | 11 |
mathematical models | 11 |
study entry | 11 |
mri scans | 11 |
critical illness | 11 |
tested positive | 11 |
mild cognitive | 11 |
weak social | 11 |
cellular immune | 11 |
control studies | 11 |
th th | 11 |
skin infections | 11 |
month old | 11 |
labour market | 11 |
gray wolves | 11 |
younger respondents | 11 |
especially among | 11 |
predicted ifrs | 11 |
health centres | 11 |
social health | 11 |
telomere shortening | 11 |
medical record | 11 |
physiological changes | 11 |
rate among | 11 |
good health | 11 |
higher proportion | 11 |
pathogenic role | 11 |
liver enzymes | 11 |
immune aging | 11 |
may enhance | 11 |
diagnostic accuracy | 11 |
limited data | 11 |
care professionals | 11 |
oxidative phosphorylation | 11 |
total ige | 11 |
body height | 11 |
systemic inflammatory | 11 |
also contribute | 11 |
mean sd | 11 |
otherwise healthy | 11 |
transcription factors | 11 |
side effect | 11 |
among different | 11 |
controlled study | 11 |
lumbar spine | 11 |
humoral immune | 11 |
urban area | 11 |
journal pre | 11 |
asymptomatic individuals | 11 |
calf circumference | 11 |
social constructions | 11 |
average annual | 11 |
acute care | 11 |
functional ability | 11 |
cystic fibrosis | 11 |
herpes simplex | 11 |
study revealed | 11 |
physical limitations | 11 |
care service | 11 |
past months | 11 |
ambulatory blood | 11 |
human immunodeficiency | 11 |
unwanted sexual | 11 |
main outcome | 11 |
body temperature | 11 |
tobacco smoke | 11 |
conducted using | 11 |
information regarding | 11 |
underlying mechanisms | 11 |
ventricular mass | 11 |
first patient | 11 |
sustained remission | 11 |
kg bw | 11 |
high percentage | 11 |
research agenda | 11 |
missing values | 11 |
free mass | 11 |
serum vitamin | 11 |
also important | 11 |
marrow failure | 11 |
three cases | 11 |
sectional survey | 11 |
mitochondrial membrane | 11 |
mixed infections | 11 |
purpura nephritis | 11 |
congenital anomalies | 11 |
clonal hematopoiesis | 11 |
different stages | 11 |
representative sample | 11 |
positron emission | 11 |
dravet syndrome | 11 |
incident cases | 11 |
antibody levels | 11 |
immune dysfunction | 11 |
tibialis anterior | 11 |
electronic medical | 11 |
genetic diagnosis | 11 |
lower extremities | 11 |
th century | 11 |
useful tool | 11 |
associated infections | 11 |
community capacity | 11 |
left leg | 11 |
climate change | 11 |
world outcomes | 11 |
molecular weight | 11 |
unknown origin | 11 |
mineral density | 11 |
home environment | 11 |
well described | 11 |
plasma creatinine | 11 |
genetic counseling | 11 |
screening program | 11 |
younger generations | 11 |
random forest | 11 |
clinically meaningful | 10 |
generational stereotypes | 10 |
caenorhabditis elegans | 10 |
treatment period | 10 |
findings support | 10 |
publicly available | 10 |
renal toxicity | 10 |
muscle atrophy | 10 |
small sample | 10 |
multiple linear | 10 |
intravascular coagulation | 10 |
mean bmi | 10 |
lessons learned | 10 |
cell cytotoxicity | 10 |
important implications | 10 |
functional outcomes | 10 |
rank test | 10 |